Across the various development stages, from Phase I to pre-registration, 101 different companies have contributed at least one novel drug candidate to the development pipeline, (Figure 3 a), indicative of the perceived opportunity that continues to exist in the medical management of obesity
NAD+ IV therapy: What the data says IV NAD+ administration offers a different way to boost NAD+ levels by skipping initial digestive processing
Guidelines for the management of squamous cell carcinoma in organ transplant recipients
C a d hp thu s t c kt qu sau 3 thng s dng
Oxygenated versus standard cold perfusion preservation in kidney transplantation (COMPARE): a randomised, double-blind, paired, phase 3 trial
Phase 2 studies showed therapeutic levels could be achieved in patients